Search results for Lintuzumab ELISA Kit
Lintuzumab ELISA Kit, ProteoGenix, KPTX206
Description of Lintuzumab ELISA Kit Introduction Lintuzumab is a monoclonal antibody that has been developed as a therapeutic agent for the treatment of acute myeloid leukemia (AML). It specifically targets the CD33 antigen, which is overexpressed on the surface of leukemic cells in AML patients. The Lintuzumab ELISA Kit is a highly sensitive and specific tool for the detection and quantification of Lintuzumab in various biological samples. In this article, we will discuss the structure, activity, and application of the Lintuzumab ELISA Kit in the field of AML research. Structure of Lintuzumab Lintuzumab is a chimeric monoclonal antibody, meaning it is composed of both human and mouse components. It is composed of two heavy chains and two light chains, each containing variable and constant regions. The variable regions of Lintuzumab are responsible for its binding specificity to the CD33 antigen, while the constant regions are responsible for its effector functions, such as antibody-dependent cell-mediated cytotoxicity (ADCC) and complement-dependent cytotoxicity (CDC). Activity of Lintuzumab The main activity of Lintuzumab is its ability to bind to the CD33 antigen on the surface of leukemic cells. This binding leads to the activation of immune effector cells, such as natural killer cells and macrophages, which then target and kill the leukemic cells. Lintuzumab also has the ability to induce apoptosis, or programmed cell death, in CD33-expressing leukemic cells. This dual mechanism of action makes Lintuzumab a potent therapeutic agent for the treatment of AML. Application of Lintuzumab ELISA Kit The Lintuzumab ELISA Kit is a valuable tool for researchers studying AML and the use of Lintuzumab as a therapeutic agent. It is a highly sensitive and specific assay that allows for the accurate quantification of Lintuzumab in various biological samples, such as serum, plasma, and cell culture supernatants. This is crucial in determining the pharmacokinetics and pharmacodynamics of Lintuzumab, as well as monitoring its levels during clinical trials. The Lintuzumab ELISA Kit can also be used to measure the levels of Lintuzumab in patient samples before and after treatment, providing valuable information on its efficacy and potential toxicity. This data can aid in the development of personalized treatment plans for AML patients. Furthermore, the Lintuzumab ELISA Kit can be used to screen potential Lintuzumab candidates in preclinical studies. This allows for the identification of the most effective Lintuzumab variants, which can then be further developed for clinical use. Future prospects The use of Lintuzumab as a therapeutic agent for AML is still in its early stages, with ongoing clinical trials evaluating its safety and efficacy. However, the promising results from preclinical studies and early clinical trials suggest that Lintuzumab has the potential to become a valuable addition to the current treatment options for AML. Conclusion In conclusion, the Lintuzumab ELISA Kit is a crucial tool for researchers studying Lintuzumab and its use as a therapeutic agent for AML. Its high sensitivity and specificity make it an ideal assay for the detection and quantification of Lintuzumab in various biological samples. With ongoing clinical trials and further research, Lintuzumab has the potential to improve the outcomes of AML patients and become a valuable addition to the current treatment options for this disease.
Host
Reactivity
Applications
Conjugation
Lintuzumab ELISA Kit, Abbexa, abx395095
Lintuzumab ELISA Kit is a quantitative ELISA kit for detection of Lintuzumab.Lintuzumab is a humanized monoclonal antibody, HuM195, that targets the cell surface antigen CD33 that is expressed on the vast majority of acute myeloid leukemia (AML) cells. [225Ac]Ac-lintuzumab clinical trials were discussed in detail in reference. An initial phase I dose-escalation trial demonstrated that for a single infusion of [225Ac]Ac-lintuzumab in patients with relapsed or refractory acute myeloid leukemia, the maximum tolerated dose (MTD) was determined to be 111 kBq/kg with antileukemic activity across all dose levels. No evidence of radiation-induced nephrotoxicity was seen. Peripheral blasts were eliminated in 63% of the patients at doses of >37 kBq/kg. Bone marrow blast reduction was observed in 67% of patients. Subsequently, a multicenter phase I dose-escalation trial was conducted to define MTD, toxicity, and response rate of fractionated-dose [225Ac]Ac-lintuzumab when combined with low-dose cytarabine (LDAC) in older patients with untreated AML who were not candidates for intensive chemotherapy.
Host
Reactivity
Human
Applications
ELISA
Conjugation
Please provide the required information below so that we can quickly source your products.